News Briefs

Teva Pharmaceuticals USA, Inc. launched the first generics of Gilead Sciences, Inc.’s Truvada (emtricitabine/tenofovir disoproxil fumarate) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate). Emtricitabine/tenofovir disoproxil fumarate is indicated for the treatment of HIV-1 in combination with other antiretroviral agents in people weighing at least 37 pounds, as well as for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk people weighing at least 77 pounds. Efavirenz/emtricitabine/tenofovir disoproxil fumarate is indicated for the treatment of HIV-1 infection in people weighing at least 88 pounds either as a complete regimen or in combination with other antiretroviral agents. The wholesale acquisition cost for a tablet of 200 mg/300 mg emtricitabine/tenofovir disoproxil fumarate is $48.51 — or $1,455.30 for 30 days — and 600 mg/200 mg/300 mg efavirenz/emtricitabine/tenofovir disoproxil fumarate’s WAC is $78.86 per tablet, or $2,365.80 for 30 days. Website Drugs.com lists the price of 30 tablets of all four dosages of Truvada as $1,932.84, and the price of 30 600 mg/200 mg/300 mg tablets of Atripla as $3,135.98. Teva has savings cards for both drugs for eligible commercially insured patients available for download; the offers expire March 29, 2021. Visit www.tevahivgenerics.com.

The United States realized $2.2 billion in savings from biosimilar use in 2019, according to the Association for Accessible Medicines report Securing Our Access & Savings: 2020 Generic Drug & Biosimilars Access & Savings in the U.S. Report. The total savings from 2010 to 2019 was almost $4.5 billion. But with 28 biosimilars approved and only 17 on the market, those delayed launches have cost the U.S. health system $9.8 billion in lost savings since 2015, according to the report, which was published Sept. 29. Download it at https://accessiblemeds.org/2020-Access-Savings-Report.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-FDA-Extends-Xeljanz-Safety-Warnings-to-Other-JAK-Inhibitors.jpg
October 14

FDA Extends Xeljanz Safety Warnings to Other JAK Inhibitors

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured_FDA-Requires-Warnings-on-Labels-of-JAK-Inhibitors-for-Inflammatory-Conditions.jpg
October 14

FDA Approves Byooviz, First Ophthalmology Biosimilar in U.S.

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-Groups-Warn-Against-Avastin-Biosimilar-Off-Label-Use-in-Eyes.jpg
October 14

Groups Warn Against Avastin Biosimilar Off-Label Use in Eyes

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today